Baseline serum osteopontin levels predict the clinical effectiveness of tocilizumab but not infliximab in biologic-Naïve patients with rheumatoid arthritis: A single-center prospective study at 1 year (the Keio First-Bio Cohort study)

Keisuke Izumi, Yuko Kaneko, Misato Hashizume, Keiko Yoshimoto, Tsutomu Takeuchi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To explore the baseline predictors of clinical effectiveness after tocilizumab or infliximab treatment in biologic-naïve rheumatoid arthritis patients. Methods: Consecutive biologic-naïve patients with rheumatoid arthritis initiating infliximab (n = 57) or tocilizumab (n = 70) treatment were included in our prospective cohort study. Our cohort started in February 2010, and the patients observed for at least 1 year as of April 2013 were analysed. We assessed baseline variables including patients' characteristics (age, sex, disease duration, prednisolone dose, methotrexate dose, other disease-modifying antirheumatic drug use, Clinical Disease Activity Index [CDAI]) and serum biomarker levels (C-reactive protein, immunoglobulin M-rheumatoid factor, anti-cyclic citrullinated protein/pep-tide antibodies, interferon-y, interleukin (IL)-1β, IL-2, IL-6, IL-8, IL-10, IL-17, tumor necrosis factor-a, soluble intercellular adhesion molecule-1, bone alkaline phosphatase, osteonectin, osteopontin) to extract factors associated with clinical remission (CDAK2.8) at 1 year using univariate analyses, and the extracted factors were entered into a multivariate logistic regression model. Similar analyses were also performed for Simplified Disease Activity Index (SDAI) remission (

Original languageEnglish
Article numbere0145468
JournalPLoS One
Volume10
Issue number12
DOIs
Publication statusPublished - 2015 Dec 1

Fingerprint

osteopontin
Osteopontin
rheumatoid arthritis
Biological Products
prospective studies
cohort studies
Rheumatoid Arthritis
Cohort Studies
Prospective Studies
remission
Serum
Osteonectin
Antirheumatic Agents
Interleukin-17
Rheumatoid Factor
Logistic Models
Tides
Biomarkers
Intercellular Adhesion Molecule-1
Prednisolone

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

@article{e861493a0a764594972da5bf9c666f54,
title = "Baseline serum osteopontin levels predict the clinical effectiveness of tocilizumab but not infliximab in biologic-Na{\"i}ve patients with rheumatoid arthritis: A single-center prospective study at 1 year (the Keio First-Bio Cohort study)",
abstract = "Objective: To explore the baseline predictors of clinical effectiveness after tocilizumab or infliximab treatment in biologic-na{\"i}ve rheumatoid arthritis patients. Methods: Consecutive biologic-na{\"i}ve patients with rheumatoid arthritis initiating infliximab (n = 57) or tocilizumab (n = 70) treatment were included in our prospective cohort study. Our cohort started in February 2010, and the patients observed for at least 1 year as of April 2013 were analysed. We assessed baseline variables including patients' characteristics (age, sex, disease duration, prednisolone dose, methotrexate dose, other disease-modifying antirheumatic drug use, Clinical Disease Activity Index [CDAI]) and serum biomarker levels (C-reactive protein, immunoglobulin M-rheumatoid factor, anti-cyclic citrullinated protein/pep-tide antibodies, interferon-y, interleukin (IL)-1β, IL-2, IL-6, IL-8, IL-10, IL-17, tumor necrosis factor-a, soluble intercellular adhesion molecule-1, bone alkaline phosphatase, osteonectin, osteopontin) to extract factors associated with clinical remission (CDAK2.8) at 1 year using univariate analyses, and the extracted factors were entered into a multivariate logistic regression model. Similar analyses were also performed for Simplified Disease Activity Index (SDAI) remission (",
author = "Keisuke Izumi and Yuko Kaneko and Misato Hashizume and Keiko Yoshimoto and Tsutomu Takeuchi",
year = "2015",
month = "12",
day = "1",
doi = "10.1371/journal.pone.0145468",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Baseline serum osteopontin levels predict the clinical effectiveness of tocilizumab but not infliximab in biologic-Naïve patients with rheumatoid arthritis

T2 - A single-center prospective study at 1 year (the Keio First-Bio Cohort study)

AU - Izumi, Keisuke

AU - Kaneko, Yuko

AU - Hashizume, Misato

AU - Yoshimoto, Keiko

AU - Takeuchi, Tsutomu

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Objective: To explore the baseline predictors of clinical effectiveness after tocilizumab or infliximab treatment in biologic-naïve rheumatoid arthritis patients. Methods: Consecutive biologic-naïve patients with rheumatoid arthritis initiating infliximab (n = 57) or tocilizumab (n = 70) treatment were included in our prospective cohort study. Our cohort started in February 2010, and the patients observed for at least 1 year as of April 2013 were analysed. We assessed baseline variables including patients' characteristics (age, sex, disease duration, prednisolone dose, methotrexate dose, other disease-modifying antirheumatic drug use, Clinical Disease Activity Index [CDAI]) and serum biomarker levels (C-reactive protein, immunoglobulin M-rheumatoid factor, anti-cyclic citrullinated protein/pep-tide antibodies, interferon-y, interleukin (IL)-1β, IL-2, IL-6, IL-8, IL-10, IL-17, tumor necrosis factor-a, soluble intercellular adhesion molecule-1, bone alkaline phosphatase, osteonectin, osteopontin) to extract factors associated with clinical remission (CDAK2.8) at 1 year using univariate analyses, and the extracted factors were entered into a multivariate logistic regression model. Similar analyses were also performed for Simplified Disease Activity Index (SDAI) remission (

AB - Objective: To explore the baseline predictors of clinical effectiveness after tocilizumab or infliximab treatment in biologic-naïve rheumatoid arthritis patients. Methods: Consecutive biologic-naïve patients with rheumatoid arthritis initiating infliximab (n = 57) or tocilizumab (n = 70) treatment were included in our prospective cohort study. Our cohort started in February 2010, and the patients observed for at least 1 year as of April 2013 were analysed. We assessed baseline variables including patients' characteristics (age, sex, disease duration, prednisolone dose, methotrexate dose, other disease-modifying antirheumatic drug use, Clinical Disease Activity Index [CDAI]) and serum biomarker levels (C-reactive protein, immunoglobulin M-rheumatoid factor, anti-cyclic citrullinated protein/pep-tide antibodies, interferon-y, interleukin (IL)-1β, IL-2, IL-6, IL-8, IL-10, IL-17, tumor necrosis factor-a, soluble intercellular adhesion molecule-1, bone alkaline phosphatase, osteonectin, osteopontin) to extract factors associated with clinical remission (CDAK2.8) at 1 year using univariate analyses, and the extracted factors were entered into a multivariate logistic regression model. Similar analyses were also performed for Simplified Disease Activity Index (SDAI) remission (

UR - http://www.scopus.com/inward/record.url?scp=84956895124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956895124&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0145468

DO - 10.1371/journal.pone.0145468

M3 - Article

C2 - 26698858

AN - SCOPUS:84956895124

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e0145468

ER -